雄激素受体拮抗剂普克鲁胺——具有双重作用机制的抗COVID-19新药  

Androgen Receptor Antagonist Pruxelutamide:a Novel Anti-CovID-19 Drug with Dual Mechanisms of Action

作　　者：童友之 马连东 TONG Youzhi;MA Liandong(Kintor Pharmaceutical Limited,Suzhou 215000,China)

机构地区：[1]苏州开拓药业股份有限公司,江苏苏州215000

出　　处：《药学进展》2023年第7期499-503,共5页Progress in Pharmaceutical Sciences

摘　　要：普克鲁胺是由开拓药业研发的第2代雄激素受体拮抗剂。针对COVID-19,该药具有双重作用机制,能通过下调血管紧张素转换酶2和跨膜丝氨酸蛋白酶2阻断新冠病毒侵入宿主细胞,并可抑制急性炎症、减轻细胞因子诱导的组织/器官损伤,对轻症、中症或重症COVID-19均有治疗效果。简介了普克鲁胺治疗COVID-19的机制与临床研究进展,旨在为COVID-19的新药研发与临床治疗提供思路。Pruxelutamide is a second-generation androgen receptor antagonist developed by Kintor Pharmaceutical Limited.In response to COVID-19,this drug has dual mechanisms of action,including blocking the entry of SARS-CoV-2 into host cells by down-regulating angiotensin-converting enzyme 2(ACE2)and transmembrane serine protease 2(TMPRSS2),as well as inhibiting acute inflammation and reducing cytokine-induced tissue/organ damage.Pruxelutamide has therapeutic benefits for patients with mild,moderate or severe COVID-19.The mechanisms and clinical research progress of pruxelutamide in the treatment of COVID-19 were briefly reviewed in this article,aiming to provide ideas for new drug development and clinical treatment of COVID-19.

关 键 词：新型冠状病毒感染 雄激素受体 普克鲁胺 细胞因子风暴 

分 类 号：R978.7[医药卫生—药品]